• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two decades of advances in clinical oncology - lessons learned and future directions.

作者信息

Banerjee Susana, Booth Christopher M, Bruera Eduardo, Büchler Markus W, Drilon Alexander, Fry Terry J, Ghobrial Irene M, Gianni Luca, Jain Rakesh K, Kroemer Guido, Llovet Josep M, Long Georgina V, Pantel Klaus, Pritchard-Jones Kathy, Scher Howard I, Tabernero Josep, Weichselbaum Ralph R, Weller Michael, Wu Yi-Long

机构信息

Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.

The Institute of Cancer Research, London, UK.

出版信息

Nat Rev Clin Oncol. 2024 Nov;21(11):771-780. doi: 10.1038/s41571-024-00945-4. Epub 2024 Oct 1.

DOI:10.1038/s41571-024-00945-4
PMID:39354161
Abstract
摘要

相似文献

1
Two decades of advances in clinical oncology - lessons learned and future directions.临床肿瘤学二十年进展——经验教训与未来方向
Nat Rev Clin Oncol. 2024 Nov;21(11):771-780. doi: 10.1038/s41571-024-00945-4. Epub 2024 Oct 1.
2
Resurgence of Ebola in Uganda: Response Strategies, Lessons Learned, and Future Directions.乌干达埃博拉疫情的卷土重来：应对策略、经验教训及未来方向
Health Sci Rep. 2025 Jun 26;8(7):e70967. doi: 10.1002/hsr2.70967. eCollection 2025 Jul.
3
The Oral HIV/AIDS Research Alliance Program: lessons learned and future directions.口腔艾滋病毒/艾滋病研究联盟项目：经验教训与未来方向。
Oral Dis. 2016 Apr;22 Suppl 1(Suppl 1):128-34. doi: 10.1111/odi.12409.
4
Five Years of Family Medicine Education in Zambia: Challenges, Milestones, and Lessons Learned.赞比亚五年的家庭医学教育：挑战、里程碑与经验教训
Fam Med. 2025 Apr 14;57(5):333-9. doi: 10.22454/FamMed.2025.569547.
5
Lessons learned from terror attacks: thematic priorities and development since 2001-results from a systematic review.从恐怖袭击中吸取的教训：2001 年以来的主题优先事项和发展——系统评价的结果。
Eur J Trauma Emerg Surg. 2022 Aug;48(4):2613-2638. doi: 10.1007/s00068-021-01858-y. Epub 2022 Jan 13.
6
Multilevel factors influence the use of a cardiovascular disease assessment tool embedded in the electronic health record in oncology care.多层次因素影响肿瘤护理中嵌入电子健康记录的心血管疾病评估工具的使用。
Transl Behav Med. 2025 Jan 16;15(1). doi: 10.1093/tbm/ibae058.
7
The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy and Radiomics Based Technologies for Immuno-Oncology Biomarker Discovery and Application.癌症免疫治疗协会关于基于液体活检和放射组学技术用于免疫肿瘤学生物标志物发现与应用的观点
Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-3791.
8
Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.慢性肾脏病中尿肽和蛋白质组生物标志物的最新进展：系统评价。
Int J Mol Sci. 2023 May 23;24(11):9156. doi: 10.3390/ijms24119156.
9
En Route Critical Care Evacuations From Rarely Utilized Partner Medical Treatment Facilities: A Case Series With Lessons Learned.从很少使用的合作医疗机构进行途中重症监护后送：一个病例系列及经验教训
Mil Med. 2023 Jul 22;188(7-8). doi: 10.1093/milmed/usac079. Epub 2022 Mar 29.
10
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives.人工智能进入肿瘤病理学领域：当前应用与未来展望。
Ann Oncol. 2025 Apr 28. doi: 10.1016/j.annonc.2025.03.006.

引用本文的文献

1
Cancer complexity: why we need a novel cancer research strategy.癌症复杂性：为何我们需要一种全新的癌症研究策略。
Front Oncol. 2025 Aug 1;15:1624467. doi: 10.3389/fonc.2025.1624467. eCollection 2025.
2
Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.转移性前列腺癌二十年的疾病演变及生物标志物指导下的临床决策制定
Int J Mol Sci. 2025 Aug 6;26(15):7593. doi: 10.3390/ijms26157593.
3
Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives.

本文引用的文献

1
Long-distance microbial mechanisms impacting cancer immunosurveillance.远距离微生物机制影响癌症免疫监视。
Immunity. 2024 Sep 10;57(9):2013-2029. doi: 10.1016/j.immuni.2024.07.020. Epub 2024 Aug 15.
2
Top advances of the year: Immunotherapy in endometrial cancer.年度重大进展：免疫疗法在子宫内膜癌中的应用。
Cancer. 2024 Sep 15;130(18):3082-3086. doi: 10.1002/cncr.35417. Epub 2024 Jul 4.
3
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
拉丁美洲国家的癌症基因组学与生物信息学：应用、挑战与前景
Front Oncol. 2025 Jul 9;15:1584178. doi: 10.3389/fonc.2025.1584178. eCollection 2025.
4
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy.前列腺癌中的T细胞衔接器疗法：免疫疗法新前沿的分子见解
Cancers (Basel). 2025 May 29;17(11):1820. doi: 10.3390/cancers17111820.
5
Diagnosis and management of cancer recurrence: a clinical update for GPs.癌症复发的诊断与管理：全科医生临床最新资讯
Br J Gen Pract. 2025 May 2;75(754):231-233. doi: 10.3399/bjgp25X741549. Print 2025 May.
6
The treatment of breast cancer in the era of precision medicine.精准医学时代的乳腺癌治疗
Cancer Biol Med. 2025 Apr 23;22(4):322-47. doi: 10.20892/j.issn.2095-3941.2024.0510.
7
Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.解析抗生素的抗癌机制：当前见解、争议及未来展望
Antibiotics (Basel). 2024 Dec 25;14(1):9. doi: 10.3390/antibiotics14010009.
8
Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma.中性粒细胞中多样的RNA甲基化模式：肝细胞癌的关键驱动因素
Clin Transl Oncol. 2025 Jun;27(6):2527-2543. doi: 10.1007/s12094-024-03756-2. Epub 2024 Dec 2.
循环肿瘤DNA引导的晚期非小细胞肺癌降阶梯靶向治疗：一项非随机对照试验
JAMA Oncol. 2024 Jul 1;10(7):932-940. doi: 10.1001/jamaoncol.2024.1779.
4
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.新辅助纳武利尤单抗和伊匹单抗治疗可切除 III 期黑色素瘤。
N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2.
5
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?可切除非小细胞肺癌的免疫治疗：回答问题还是质疑答案？
Cancer Cell. 2024 May 13;42(5):727-731. doi: 10.1016/j.ccell.2024.04.005. Epub 2024 May 2.
6
3-year invasive disease-free survival with chemotherapy de-escalation using an F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.基于 F-FDG-PET 的、基于病理完全缓解的适应性策略在 HER2 阳性早期乳腺癌（PHERGain）中进行化疗降级的 3 年无侵袭性疾病生存：一项随机、开放标签、2 期试验。
Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3.
7
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.辅助和新辅助免疫疗法在肝细胞癌中的应用。
Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.
8
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.珐瑯质蛋白相关细胞黏附分子阳性、铂类耐药卵巢癌中的 Mirvetuximab Soravtansine。
N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169.
9
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development.加速儿科战略论坛的影响：多利益相关者会议在肿瘤药物开发中的价值评估。
J Natl Cancer Inst. 2024 Feb 8;116(2):200-207. doi: 10.1093/jnci/djad239.
10
Immunosurveillance in clinical cancer management.临床癌症管理中的免疫监测。
CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25.